EDMONTON, Jan. 19 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer of products for the treatment of multiple sclerosis (MS), announced
today that it has received clearance from the United States Food and Drug
Administration (FDA) of its Investigational New Drug Application (IND) for the
initiation of a pivotal phase III clinical trial to investigate the use of
MBP8298 as a treatment for patients with secondary progressive MS.
